<DOC>
	<DOCNO>NCT00607035</DOCNO>
	<brief_summary>The purpose study investigate combination therapy effective improve blood pressure ( BP ) reduce target organ damage Japanese hypertensive patient : Angiotensin II receptor blocker ( ARB ) plus calcium channel blocker ( CCB ) ARB plus diuretic .</brief_summary>
	<brief_title>The Japan-Combined Treatment With Olmesartan Calcium Channel Blocker Versus Olmesartan Diuretics Randomized Efficacy Study ( J-CORE )</brief_title>
	<detailed_description>Renin-angiotensin ( RA ) inhibitor demonstrate effective drug reduce subclinical target organ damage hypertensive patient . In several patient , however , BP control sufficiently achieve RA inhibitor alone , combination two drug frequently require . It unclear whether combination RA inhibitor diuretic CCB effective reduce hypertensive target organ damage . Control central BP show effective peripheral BP predict cardiovascular event target organ damage associate hypertension . The J-CORE study active control , 2-arm parallel group comparison , prospective randomize open blind end-point ( PROBE ) design study . The ARB plus CCB combination therapy group administer olmesartan 20 mg/day azelnidipine 16 mg/day ARB plus diuretic combination therapy group receive olmesartan 20 mg/day hydrochlorothiazide ( HCTZ ) 12.5 mg/day . At least 100 patient enrol group follow duration 24 week . The primary endpoint compare change central aortic BP ambulatory BP two group . The secondary endpoint compare change office BP , home BP , hypertensive target organ damage two group .</detailed_description>
	<mesh_term>Olmesartan</mesh_term>
	<mesh_term>Olmesartan Medoxomil</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<mesh_term>Diuretics</mesh_term>
	<mesh_term>Calcium Channel Blockers</mesh_term>
	<criteria>Hypertensive outpatient age 30 year old , less 85 year ( time inform consent ) , regardless sex Office systolic BP/diastolic BP &gt; 140/90 mmHg sit position even treatment olmesartan 20 mg/day 3 month . Secondary hypertension malignant hypertension History myocardial infarction cerebrovascular accident within 6 month prior screen Percutaneous transluminal coronary angioplasty ( PTCA ) coronary artery bypass grafting ( CABG ) do within 6 month screen schedule Current treatment congestive cardiac failure ( New York Heart Association [ NYHA ] functional class II severer ) ejection fraction ＜40 % Atrial fibrillation atrial flutter Renal dysfunction ( serum creatinine ≥2 mg/dl ) Hepatic dysfunction ( AST and/or ALT ≥100 IU/l )</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>May 2008</verification_date>
</DOC>